ABSTRACT
Introduction Historically, liver imaging using radionuclides focused on the detection of liver
masses. More recently, anatomic imaging modalities including ultrasound, CT and MRI have replaced colloid imaging because of their greater sensitivity and ability to distinguish cystic from solid lesions. Solid masses may nevertheless have a nonspecific appearance on anatomic imaging requiring the use of radiopharmaceuticals that identify certain cell lines, metabolic properties or surface characteristics of specific lesions. The modern technetium-99m labeled hepatobiliary agents retain a pivotal role in studying biliary flow and dynamics.
